Compare VCIG & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCIG | DCOY |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 656.7K | 674.8K |
| IPO Year | 2022 | 2014 |
| Metric | VCIG | DCOY |
|---|---|---|
| Price | $5.80 | $1.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 55.7K |
| Earning Date | 10-16-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.42 |
| P/E Ratio | $1.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.53 |
| 52 Week High | $23.40 | $67.68 |
| Indicator | VCIG | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 73.47 | 37.32 |
| Support Level | $0.57 | $0.90 |
| Resistance Level | $11.58 | $1.24 |
| Average True Range (ATR) | 0.88 | 0.08 |
| MACD | 0.69 | 0.07 |
| Stochastic Oscillator | 63.63 | 64.71 |
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.